Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated “Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer’s disease” HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna.The presentation, titled, “A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Mod
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.MarketBeat
- Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome ProgramBusiness Wire
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Exosome Therapeutics Market Report 2025: 120+ Drug Candidates in Pipeline, Market to Reach $1.4 Billion by 2040, Growing at 41.1% CAGR [Yahoo! Finance]Yahoo! Finance
COYA
Sec Filings
- 3/18/25 - Form 10-K
- 3/18/25 - Form 8-K
- 2/25/25 - Form 4
- COYA's page on the SEC website